Original Article

Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review

Gonzales et al.

Objective: Palivizumab is a humanized monoclonal antibody approved for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) in infants and young children at high risk of RSV disease. This systematic review summarized evidence on the effectiveness and safety of palivizumab when used in approved populations.

Key Points

• Systematic review supports the positive benefit-risk profile of palivizumab in the indicated populations.

• Real-world safety and effectiveness of palivizumab are consistent with Phase III trials results.

• Palivizumab reduces RSV-related hospitalizations, ICU admissions, and need for mechanical ventilation.